Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support
Open Access
- 1 April 1996
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 73 (8), 979-984
- https://doi.org/10.1038/bjc.1996.191
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approachBritish Journal of Cancer, 1995
- Pilot Study of a High-Dose Carboplatin-Based Salvage Strategy for Relapsing or Refractory Germ Cell CancerCancer Investigation, 1995
- Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: Effect of graft sizeAnnals of Oncology, 1994
- Limited-sampling models for anticancer agentsZeitschrift für Krebsforschung und Klinische Onkologie, 1994
- High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.Journal of Clinical Oncology, 1994
- Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combinationCancer Chemotherapy and Pharmacology, 1994
- High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.Journal of Clinical Oncology, 1993
- Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.1993
- Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.Journal of Clinical Oncology, 1993
- High-dose carboplatin in refractory ovarian cancer patients.Journal of Clinical Oncology, 1987